ライフサイエンスコーパス: serous carcinoma

1 clusion cysts to a conventional (high-grade) serous carcinoma.

2 53 allele occurs early in the development of serous carcinoma.

3 rotransposition events in high-grade ovarian serous carcinoma.

4 shows prognostic significance for high-grade serous carcinoma.

5 tions for mucinous, clear-cell, or low-grade serous carcinoma.

6 cer, including the highly aggressive ovarian serous carcinoma.

7 way activation have been reported in ovarian serous carcinoma.

8 greater GC UNC-45 expression than low-stage serous carcinoma.

9 s to noninvasive and invasive micropapillary serous carcinomas.

10 tage serous BOTs and later developed grade 1 serous carcinomas.

11 hways through profiling of normal FTSECs and serous carcinomas.

12 type II OvCAs, most of which are high-grade serous carcinomas.

13 er was significantly higher in HG than in LG serous carcinomas.

14 vely, in independent 47 affinity-purified HG serous carcinomas.

15 p13.12 in 6 of 31 (19.5%) ovarian high-grade serous carcinomas.

16 oved disease-specific survival in high-grade serous carcinoma (0.71, 0.55-0.91; p=0.0080), but weak P

17 n cancer were included: 1742 with high-grade serous carcinoma, 110 with low-grade serous carcinoma, 2

18 rcinomas (6.7%) and 5 of 26 type II uterine (serous) carcinomas (19.2%).

19 h-grade serous carcinoma, 110 with low-grade serous carcinoma, 207 with mucinous carcinoma, 484 with

20 s borderline tumors, but among the low-grade serous carcinomas (39 stage III, 2 stage II, and 2 stage

21 R-2 expression and amplification was seen in serous carcinoma (43% and 29%), while grade 1 endometrio

22 Thirty-four uterine serous carcinomas, a type of endometrial carcinoma with

23 ive histological subtypes (uterine papillary serous carcinoma and clear cell carcinoma, UPSC/CCC) by

24 the majority representing uterine papillary serous carcinoma and mixed malignant mesodermal tumor.

25 a demonstrate that MI is uncommon in uterine serous carcinoma and support that different pathogenetic

26 Women age < 35 years with low-grade serous carcinoma and those with persistent disease at co

27 ian tumors (BOT) can progress into low-grade serous carcinomas and have relatively indolent clinical

28 except frequent p53 mutations in high-grade serous carcinomas and malignant mixed mesodermal tumors

29 fimbria as a field of origin for high-grade serous carcinomas and present a binary model of ovarian

30 -1 is significantly overexpressed in ovarian serous carcinomas and several other types of carcinomas.

31 arian neoplastic lesions, especially uterine serous carcinomas, and suggest that mutation of PPP2R1A

32 , and seromucinous carcinomas; ii) low-grade serous carcinomas; and iii) mucinous carcinomas and mali

33 ate that the precursor of ovarian high-grade serous carcinoma appears to develop from an occult intra

34 Low-grade ovarian serous carcinomas are believed to arise via an adenoma-s

35 indings, suggests that aggressive, low-grade serous carcinomas are more likely derived from serous bo

36 Because serous carcinomas are the most common EOC and account fo

37 ors (SBTs), putative precursors of low-grade serous carcinomas, are among the few human neoplasms wit

38 of the PI3K pathway, we show that high-grade serous carcinomas arise from the fallopian tube in mice.

39 found that advanced-stage, low-grade ovarian serous carcinomas both with and without adjacent serous

40 r cell carcinoma (Arid1a, Pik3ca), low-grade serous carcinoma (Braf), endometrioid (Ctnnb1), or mucin

41 en observed at high frequency in endometrial serous carcinomas but at low frequency in ovarian clear

42 Hemizygous ch1p36 deletion was common in LG serous carcinomas but was rarely seen in SBT.

43 face epithelial cell line and in a low-grade serous carcinoma cell line that expressed undetectable l

44 Most notable of these tumours are papillary serous carcinomas, clear-cell carcinomas, carcinosarcoma

45 High-grade (HG) serous carcinomas contain frequent TP53 mutations, where

46 Immunohistochemistry studies in ovarian serous carcinomas demonstrate that NAC-1 is localized in

47 against i.p. chemotherapy-resistant uterine serous carcinoma-derived xenografts compared with free E

48 hat Nrf2 was highly expressed in endometrial serous carcinoma (ESC), whereas complex hyperplasia and

49 rast, none of 71 type II ovarian (high-grade serous) carcinomas exhibited PPP2R1A mutations.

50 Serous carcinoma expressed elevated levels of GC UNC-45

51 ated endometrioid, clear cell, and low-grade serous carcinomas from high-grade serous and mucinous ca

52 Endometrioid and low-grade serous carcinomas had similar correlation coefficients (

53 of deletion of tumor suppressors in ovarian serous carcinomas has not been well studied.

54 common subtype of ovarian cancer, high-grade serous carcinoma, has sparked a major effort within the

55 High-grade serous carcinoma (HGSC) is the most prevalent and lethal

56 g evidence indicates that ovarian high-grade serous carcinoma (HGSC) originates from fallopian tube s

57 lantable murine models of ovarian high grade serous carcinoma (HGSC) remain an important research too

58 Ovarian high-grade serous carcinoma (HGSC) results in the highest mortality

59 lantable murine models of ovarian high-grade serous carcinoma (HGSC) with regard to mutations in the

60 ocus has been detected in ovarian high-grade serous carcinoma (HGSC), the most common and malignant t

61 cantly increased risk for ovarian high-grade serous carcinoma (HGSC; 3.8% cases vs. 0.2% controls).

62 al fallopian tube among all cases.High-grade serous carcinomas (HGSCs) are associated with precursor

63 Many high-grade serous carcinomas (HGSCs) of the pelvis are thought to o

64 e Atlas (TCGA), of which 169 were high-grade serous carcinomas (HGSCs).

65 cent studies suggest that >50% of high-grade serous carcinomas involving the ovary likely arise from

66 in the MI frequency between endometrioid and serous carcinoma is statistically significant (P = 0.003

67 common surface epithelial tumors, low-grade serous carcinoma is the prototypic type I tumor and high

68 s the prototypic type I tumor and high-grade serous carcinoma is the prototypic type II tumor.

69 cular pathogenesis of fallopian tube-derived serous carcinomas is poorly understood and there are few

70 l cancers collectively referred to as pelvic serous carcinomas, is not well known.

71 profiled the DNA methylomes of 12 low-grade serous carcinomas (LGSCs), 19 SBOTs, and 16 benign serou

72 carcinoma (log-rank p<0.0001) and high-grade serous carcinoma (log-rank p=0.0006), and ER expression

73 Type II tumors include high-grade serous carcinoma, malignant mixed mesodermal tumors (car

74 e tumors (SBTs), non-invasive micropapillary serous carcinomas (MPSCs), and invasive micropapillary s

75 (n = 43) but were found in 73% of high-grade serous carcinomas (n = 18).

76 rous borderline tumors (n = 30) or low-grade serous carcinomas (n = 43) but were found in 73% of high

77 Although uterine papillary serous carcinoma of the endometrium represents only 3% t

78 Low-grade serous carcinoma of the ovary (LGSOC) or peritoneum (LGS

79 Low-grade serous carcinoma of the ovary is chemoresistant but muta

80 tive in the treatment of recurrent low-grade serous carcinoma of the ovary or peritoneum.

81 erapy in women with stage II to IV low-grade serous carcinoma of the ovary or peritoneum.

82 a deep analysis of one patient with advanced serous carcinoma of the ovary.

83 Papillary serous carcinoma of the peritoneum (PSCP) is believed to

84 loss patterns on chromosome 17 to papillary serous carcinoma of the peritoneum (PSCP) which is histo

85 h a platinum- and taxane-resistant papillary serous carcinoma of the peritoneum experienced a partial

86 n tube are putative precursors to high-grade serous carcinomas of the ovary and peritoneum.

87 Uterine serous carcinoma, one of the most aggressive types of en

88 g squamous cell carcinoma (LSCC) and ovarian serous carcinoma (OSC).

89 re common type of ovarian cancer, high-grade serous carcinoma, ovarian CCC is often resistant to plat

90 ation of chemotherapy in ovarian and uterine serous carcinoma patients by biodegradable nanoparticles

91 cated that full-length ALK expression in two serous carcinoma patients is consistent with ALK gene co

92 detected aberrant ALK expression in 2% to 4% serous carcinoma patients.

93 important role early in the pathogenesis of serous carcinoma, possibly accounting for its aggressive

94 A diagnosis of primary peritoneal serous carcinoma (PPSC) requires exclusion of a source i

95 helial ovarian carcinoma (EOC) or peritoneal serous carcinoma (PSC) who had experienced disease progr

96 arise via an adenoma-serous borderline tumor-serous carcinoma sequence.

97 In contrast, in HG serous carcinomas, significant numbers of amplifications

98 r involves a genetically unstable high-grade serous carcinoma that metastasizes rapidly (type II).

99 e composed, for the most part, of high-grade serous carcinomas that can be further subdivided into mo

100 Ovarian serous carcinoma, the most common and lethal type of ova

101 xpression was frequently detected in ovarian serous carcinomas, the most common and lethal type of ov

102 number alterations in 31 high-grade ovarian serous carcinomas, the most lethal gynecologic neoplasti

103 ll as a cell of origin for high-grade pelvic serous carcinomas, the need to develop tools and model s

104 cally resembled the in situ precursor of TII serous carcinomas; these lesions have not been observed

105 and ex vivo paclitaxel resistance in ovarian serous carcinoma tissues and cell lines.

106 among patients with stage II to IV low-grade serous carcinoma treated with primary surgery followed b

107 In contrast, high-grade (conventional serous carcinoma) tumors contained wild-type K-ras in al

108 In addition to low-grade serous carcinomas, type I tumors are composed of mucinou

109 Uterine papillary serous carcinoma (UPSC) is an aggressive subtype of endo

110 Uterine serous carcinoma (USC) is a biologically aggressive subt

111 Uterine serous carcinoma (USC) is an uncommon but aggressive typ

112 serous BOTs and subsequent grade 1 papillary serous carcinomas was microdissected and retrieved using

113 High-grade serous carcinoma, which often arises from the fallopian

114 enome-wide homozygous deletion profile in HG serous carcinomas, which can serve as a molecular founda

115 BRAF mutations in advanced-stage, low-grade serous carcinomas, which contrasts with previous finding

116 cinomas (MPSCs), and invasive micropapillary serous carcinomas, which represent a morphological conti

117 nclusion Women with stage II to IV low-grade serous carcinoma who received HMT after primary treatmen

118 trioid adenocarcinomas and uterine papillary serous carcinomas, ZEB1 could be expressed in the epithe